Chris K Rayner Mbbs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5041957/publications.pdf

Version: 2024-02-01

191 papers 7,241 citations

47006 47 h-index 71685 **76** g-index

194 all docs

194 docs citations

194 times ranked 5898 citing authors

#	Article	IF	CITATIONS
1	Sensing Intra―and Extra ellular Ca ²⁺ in the Islet of Langerhans. Advanced Functional Materials, 2022, 32, 2106020.	14.9	O
2	Plasma GLP-1 Response to Oral and Intraduodenal Nutrients in Health and Type 2 Diabetesâ€"Impact on Gastric Emptying. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1643-e1652.	3.6	15
3	Measurement of Gastric Emptying Using a 13C-octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 751-757.	1.2	7
4	Nutrition Management for Critically Ill Adult Patients Requiring Non-Invasive Ventilation: A Scoping Review. Nutrients, 2022, 14, 1446.	4.1	9
5	Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2â€hour plasma glucose in individuals without diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1132-1142.	4.4	7
6	Geospatial analysis of <scp><i>Helicobacter pylori</i></scp> infection in South Australia: Should location influence eradication therapy?. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1263-1274.	2.8	7
7	Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit. Diabetes, Obesity and Metabolism, 2022, 24, 1182-1184.	4.4	8
8	Effects of ileal glucose infusion on enteropancreatic hormone secretion in humans: relationship to glucose absorption. Metabolism: Clinical and Experimental, 2022, 131, 155198.	3.4	1
9	Increasing <i>Helicobacter pylori</i> clarithromycin resistance in Australia over 20 years. Internal Medicine Journal, 2022, 52, 1554-1560.	0.8	11
10	Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in TypeÄ2 Diabetes, Associated with Slowing of Gastric Emptying. Diabetes Therapy, 2022, 13, 1245-1249.	2.5	2
11	Cholecystectomy is associated with dysglycaemia: Crossâ€sectional and prospective analyses. Diabetes, Obesity and Metabolism, 2022, 24, 1656-1660.	4.4	6
12	Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3850-e3856.	3.6	7
13	Gastrointestinal adverse events with insulin glargine/lixisenatide fixedâ€ratio combination versus glucagonâ€rike peptideâ€1 receptor agonist <scp>s</scp> in people with type 2 diabetes mellitus: A network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 136-146.	4.4	12
14	Gastric emptying in health and type 2 diabetes: An evaluation using a 75Âg oral glucose drink. Diabetes Research and Clinical Practice, 2021, 171, 108610.	2.8	14
15	Antibiotic resistance of <i>Helicobacter pylori</i> in Australia and New Zealand: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1450-1456.	2.8	16
16	Sucralose can improve glucose tolerance and upregulate expression of sweet taste receptors and glucose transporters in an obese rat model. European Journal of Nutrition, 2021, 60, 1809-1817.	3.9	8
17	Spontaneous or Deliberate: Effects of Acute Variations in Glycemia on Gastric Emptying in Type 1 Diabetes. Diabetes Care, 2021, 44, 316-318.	8.6	5
18	Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease. Nutrients, 2021, 13, 1104.	4.1	53

#	Article	IF	CITATIONS
19	Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2411-2413.	4.4	2
20	A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans. Gastroenterology, 2021, 161, 536-547.e2.	1.3	10
21	Twincretin therapy for type 2 diabetes: how do two do?. Lancet, The, 2021, 398, 560-561.	13.7	1
22	Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. Nutrients, 2021, 13, 2826.	4.1	9
23	Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 326, 1213.	7.4	3
24	Comparison of Cap-Assisted vs Conventional Endoscopic Technique for Management of Food Bolus Impaction in the Esophagus: Results of a Multicenter Randomized Controlled Trial. American Journal of Gastroenterology, 2021, 116, 2235-2240.	0.4	9
25	Diabetic gastroparesis., 2021,, 237-253.		1
26	Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518. Diabetes Care, 2021, 44, e194-e195.	8.6	1
27	Acceleration of Gastric Emptying by Insulin-Induced Hypoglycemia is Dependent on the Degree of Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 364-371.	3.6	6
28	Role of endogenous glucagonâ€like peptideâ€1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 383-392.	4.4	10
29	Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 51-58.	4.4	14
30	Mechanism of glucoseâ€lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes, Obesity and Metabolism, 2020, 22, 141-148.	4.4	60
31	The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. Acta Diabetologica, 2020, 57, 583-587.	2.5	5
32	Disparities in gastric emptying and postprandial glycaemia between Han Chinese and Caucasians with type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107951.	2.8	11
33	Statins and glycaemic control in type 2 diabetes: Are bile acids relevant?. British Journal of Clinical Pharmacology, 2020, 86, 2538-2539.	2.4	О
34	Gastrointestinal autonomic neuropathy in diabetes. Autonomic Neuroscience: Basic and Clinical, 2020, 229, 102718.	2.8	16
35	Role of intestinal glucose absorption in glucose tolerance. Current Opinion in Pharmacology, 2020, 55, 116-124.	3.5	15
36	Comparative Effects of Intraduodenal Glucose and Fat Infusion on Blood Pressure and Heart Rate in Type 2 Diabetes. Frontiers in Nutrition, 2020, 7, 582314.	3.7	2

#	Article	IF	CITATIONS
37	Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin. Pharmaceuticals, 2020, 13, 410.	3.8	4
38	Glucagonâ€like peptideâ€1 receptor agonists and the appropriate measurement of gastric emptying. Diabetes, Obesity and Metabolism, 2020, 22, 2504-2506.	4.4	17
39	Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. Pharmaceutics, 2020, 12, 790.	4.5	23
40	Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2020, 43, 1813-1821.	8.6	19
41	Effects of Proximal and Distal Enteral Glucose Infusion on Cardiovascular Response in Health and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2877-e2884.	3.6	4
42	Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients, 2020, 12, 1962.	4.1	13
43	Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steadyâ€state concentrations. Diabetes, Obesity and Metabolism, 2020, 22, 788-797.	4.4	39
44	A Multiplexed Microfluidic Platform toward Interrogating Endocrine Function: Simultaneous Sensing of Extracellular Ca ²⁺ and Hormone. ACS Sensors, 2020, 5, 490-499.	7.8	6
45	Development of innovative tools for investigation of nutrient-gut interaction. World Journal of Gastroenterology, 2020, 26, 3562-3576.	3.3	8
46	Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6201-6206.	3.6	15
47	A randomized, crossover study of the acute effects of acarbose and gastric distension, alone and combined, on postprandial blood pressure in healthy older adults. BMC Geriatrics, 2019, 19, 241.	2.7	4
48	The prevalence and impact of low faecal elastase-1 in community-based patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 156, 107822.	2.8	5
49	Gastric Emptying in Patients With Well-Controlled Type 2 Diabetes Compared With Young and Older Control Subjects Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3311-3319.	3.6	58
50	Longitudinal evaluation of gastric emptying in type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 154, 27-34.	2.8	8
51	Is Making the Stomach Pump Better the Answer to Gastroparesis?. Gastroenterology, 2019, 156, 1555-1557.	1.3	12
52	Secretion of Gut Hormones and Expression of Sweet Taste Receptors and Glucose Transporters in a Rat Model of Obesity. Obesity Facts, 2019, 12, 190-198.	3.4	4
53	Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. Diabetes Care, 2019, 42, 520-528.	8.6	37
54	Sugar Responses of Human Enterochromaffin Cells Depend on Gut Region, Sex, and Body Mass. Nutrients, 2019, 11, 234.	4.1	19

#	Article	IF	CITATIONS
55	Combination of laser and human adipose-derived stem cells in repair of rabbit anal sphincter injury: a new therapeutic approach. Stem Cell Research and Therapy, 2019, 10, 367.	5.5	9
56	The Effects of a Whey Protein and Guar Gum-Containing Preload on Gastric Emptying, Glycaemia, Small Intestinal Absorption and Blood Pressure in Healthy Older Subjects. Nutrients, 2019, 11, 2666.	4.1	9
57	Diabetic Gastroparesis and Glycaemic Control. Current Diabetes Reports, 2019, 19, 153.	4.2	23
58	A whey/guar "preload―improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12â€week, singleâ€blind, randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 930-938.	4.4	35
59	Title: Differentiating the effects of whey protein and guar gum preloads on postprandial glycemia in type 2 diabetes. Clinical Nutrition, 2019, 38, 2827-2832.	5.0	21
60	Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1158-1167.	4.4	38
61	Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1251-1254.	4.4	12
62	Hypoglycaemia and gastric emptying. Diabetes, Obesity and Metabolism, 2019, 21, 491-498.	4.4	20
63	Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagonâ€like peptideâ€l, and gastric emptying after oral glucose, in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 640-647.	4.4	31
64	Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2019, 21, 700-704.	4.4	29
65	Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management. Diabetes Care, 2018, 41, 627-637.	8.6	100
66	Augmented capacity for peripheral serotonin release in human obesity. International Journal of Obesity, 2018, 42, 1880-1889.	3.4	58
67	Glucagon receptor signalling – backwards and forwards. Expert Opinion on Investigational Drugs, 2018, 27, 135-138.	4.1	7
68	Comment on Russell-Jones et al. Diabetes Care 2017;40:943–950. Comment on Bowering et al. Diabetes Care 2017;40:951–957. Diabetes Care, 2018, 41, e27-e28.	8.6	0
69	Targeting postprandial glycaemia in children with diabetes: <scp>O</scp> pportunities and challenges. Diabetes, Obesity and Metabolism, 2018, 20, 766-774.	4.4	3
70	Impact of variations in duodenal glucose load on insulin clearance in health and type 2 diabetes. Acta Diabetologica, 2018, 55, 205-207.	2.5	0
71	Comparative effects of small intestinal glucose on blood pressure, heart rate, and noradrenaline responses in obese and healthy subjects. Physiological Reports, 2018, 6, e13610.	1.7	1
72	Gut Mechanisms Linking Intestinal Sweet Sensing to Glycemic Control. Frontiers in Endocrinology, 2018, 9, 741.	3.5	24

#	Article	IF	CITATIONS
73	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4409-4418.	3.6	17
74	Role of Intestinal Bitter Sensing in Enteroendocrine Hormone Secretion and Metabolic Control. Frontiers in Endocrinology, 2018, 9, 576.	3.5	42
75	Gastric Emptying and the Personalized Management of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3503-3506.	3.6	5
76	Effects of intraduodenal administration of the artificial sweetener sucralose on blood pressure and superior mesenteric artery blood flow in healthy older subjects. American Journal of Clinical Nutrition, 2018, 108, 156-162.	4.7	7
77	Agonism of receptors in the gut–pancreas axis in type 2 diabetes: are two better than one?. Lancet, The, 2018, 391, 2577-2578.	13.7	6
78	Plasma endocannabinoid levels in lean, overweight, and obese humans: relationships to intestinal permeability markers, inflammation, and incretin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E489-E495.	3.5	41
79	Effects of Glutamine on Gastric Emptying of Low- and High-Nutrient Drinks in Healthy Young Subjects—Impact on Glycaemia. Nutrients, 2018, 10, 739.	4.1	7
80	Duodenal fatty acid sensor and transporter expression following acute fat exposure in healthy lean humans. Clinical Nutrition, 2017, 36, 564-569.	5.0	23
81	Upper and/or lower gastrointestinal adverse events with glucagonâ€like peptideâ€l receptor agonists: <scp>I</scp> ncidence and consequences. Diabetes, Obesity and Metabolism, 2017, 19, 672-681.	4.4	53
82	Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 59-63.	2.0	13
83	Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes. Diabetes Care, 2017, 40, 702-705.	8.6	14
84	Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine. Diabetes, 2017, 66, 2144-2149.	0.6	99
85	Gut feelings about diabetes and <scp>GLP</scp> †receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders. Diabetes, Obesity and Metabolism, 2017, 19, 309-312.	4.4	9
86	New insights into the anti-diabetic actions of metformin: from the liver to the gut. Expert Review of Gastroenterology and Hepatology, 2017, 11, 157-166.	3.0	38
87	Gastrointestinal motility in people with type 1 diabetes and peripheral neuropathy. Diabetologia, 2017, 60, 2312-2313.	6.3	2
88	Comparative effects of intraduodenal fat and glucose on the gut-incretin axis in healthy males. Peptides, 2017, 95, 124-127.	2.4	16
89	Expression of sweet taste receptor and gut hormone secretion in modelled type 2 diabetes. General and Comparative Endocrinology, 2017, 252, 142-149.	1.8	12
90	Whey Protein and Diabetes. , 2017, , 197-209.		2

#	Article	IF	CITATIONS
91	Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 290-293.	4.4	48
92	Reactive hypoglycaemia with seizure following intraduodenal glucose infusion in a patient with type 2 diabetes. Acta Diabetologica, 2017, 54, 215-218.	2.5	1
93	Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance. Physiological Reports, 2017, 5, e13122.	1.7	11
94	The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes, 2016, 65, 269-275.	0.6	56
95	Roles of the Gut in Glucose Homeostasis. Diabetes Care, 2016, 39, 884-892.	8.6	155
96	Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4769-4778.	3.6	14
97	DPP-4 Inhibition and the Known Unknown. Diabetes, 2016, 65, 2124-2126.	0.6	4
98	Inter-regulation of gastric emptying and incretin hormone secretion: implications for postprandial glycemic control. Biomarkers in Medicine, 2016, 10, 1167-1179.	1.4	15
99	Regional specificity of the gut-incretin response to small intestinal glucose infusion in healthy older subjects. Peptides, 2016, 86, 126-132.	2.4	3
100	Associated factors in <i>Streptococcus bovis</i> bacteremia and colorectal cancer. Kaohsiung Journal of Medical Sciences, 2016, 32, 196-200.	1.9	34
101	Effects of Fat and Protein Preloads on Pouch Emptying, Intestinal Transit, Glycaemia, Gut Hormones, Glucose Absorption, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass. Obesity Surgery, 2016, 26, 77-84.	2.1	17
102	A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes. Diabetes Care, 2016, 39, 511-517.	8.6	72
103	Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology, 2016, 16, 164-180.	1.1	71
104	Novel insights into the effects of diabetes on gastric motility. Expert Review of Gastroenterology and Hepatology, 2016, 10, 581-593.	3.0	11
105	Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition, 2016, 103, 66-70.	4.7	96
106	Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled trial. Nutrition, 2016, 32, 553-559.	2.4	10
107	Effect of duodenal glucose load on blood pressure in type 2 diabetes. Diabetes Research and Clinical Practice, 2016, 113, 38-40.	2.8	3
108	Comparative Effects of Bile Diversion and Duodenal-Jejunal Bypass on Glucose and Lipid Metabolism in Male Diabetic Rats. Obesity Surgery, 2016, 26, 1565-1575.	2.1	10

#	Article	IF	CITATIONS
109	Letter to the Editor: One-Hour Postload Hyperglycemia is a Stronger Predictor of Type 2 Diabetes than Impaired Fasting Glucose. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L33-L34.	3.6	O
110	Whey protein: The "whey―forward for treatment of type 2 diabetes?. World Journal of Diabetes, 2015, 6, 1274.	3.5	64
111	Gastric Emptying in the Elderly. Clinics in Geriatric Medicine, 2015, 31, 339-353.	2.6	58
112	Ethnic disparities in insulin and glucose-dependent insulinotropic peptide (GIP) responses to intraduodenal glucose in health. Acta Diabetologica, 2015, 52, 817-819.	2.5	2
113	Incretins. Handbook of Experimental Pharmacology, 2015, 233, 137-171.	1.8	45
114	Sustained effects of a protein â€~preload' on glycaemia and gastric emptying over 4 weeks in patients with type 2 diabetes: A randomized clinical trial. Diabetes Research and Clinical Practice, 2015, 108, e31-e34.	2.8	51
115	Relationships of Early And Late Glycemic Responses With Gastric Emptying During An Oral Glucose Tolerance Test. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3565-3571.	3.6	72
116	Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia, 2015, 58, 1769-1778.	6.3	36
117	Gastric Emptying Is More Rapid in Adolescents With Type 1 Diabetes and Impacts on Postprandial Glycemia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2248-2253.	3.6	44
118	Gastric emptying and glycaemia in health and diabetes mellitus. Nature Reviews Endocrinology, 2015, 11 , $112-128$.	9.6	197
119	Decreased Gastric Motility in Type II Diabetic Patients. BioMed Research International, 2014, 2014, 1-6.	1.9	18
120	Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E830-E837.	3.5	15
121	Impact of gastric emptying to the glycemic and insulinemic responses to a 75-g oral glucose load in older subjects with normal and impaired glucose tolerance. Physiological Reports, 2014, 2, e12204.	1.7	22
122	Changes in meal composition and duration affect postprandial endothelial function in healthy humans. American Journal of Physiology - Renal Physiology, 2014, 307, G1191-G1197.	3.4	9
123	Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia. Diabetes, 2014, 63, 785-790.	0.6	120
124	Protein â€~pre-loads' in type 2 diabetes: what do we know and what do we need to find out?. Diabetologia, 2014, 57, 2603-2604.	6.3	0
125	The Effects of Critical Illness on Intestinal Glucose Sensing, Transporters, and Absorption*. Critical Care Medicine, 2014, 42, 57-65.	0.9	74
126	Glucose absorption in small intestinal diseases. Expert Review of Gastroenterology and Hepatology, 2014, 8, 301-312.	3.0	18

#	Article	IF	CITATIONS
127	Pancreatic Enzyme Supplementation Improves the Incretin Hormone Response and Attenuates Postprandial Glycemia in Adolescents With Cystic Fibrosis: A Randomized Crossover Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2486-2493.	3.6	69
128	Small Intestinal Glucose Exposure Determines the Magnitude of the Incretin Effect in Health and Type 2 Diabetes. Diabetes, 2014, 63, 2668-2675.	0.6	46
129	Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?. Diabetes Research and Clinical Practice, 2014, 106, e3-e6.	2.8	59
130	Rapid gastric and intestinal transit is a major determinant of changes in blood glucose, intestinal hormones, glucose absorption and postprandial symptoms after gastric bypass. Obesity, 2014, 22, 2003-2009.	3.0	98
131	Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index. American Journal of Physiology - Renal Physiology, 2014, 307, G958-G967.	3.4	43
132	Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2628-E2634.	3.6	32
133	Measurement of gastric emptying in diabetes. Journal of Diabetes and Its Complications, 2014, 28, 894-903.	2.3	34
134	Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin. Diabetes, 2014, 63, 2776-2787.	0.6	45
135	Disordered Control of Intestinal Sweet Taste Receptor Expression and Glucose Absorption in Type 2 Diabetes. Diabetes, 2013, 62, 3532-3541.	0.6	88
136	Gut motility and enteroendocrine secretion. Current Opinion in Pharmacology, 2013, 13, 928-934.	3.5	68
137	Effects of Taurocholic Acid on Glycemic, Glucagon-like Peptide-1, and Insulin Responses to Small Intestinal Glucose Infusion in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E718-E722.	3.6	74
138	Diabetic gastroparesis: recent insights into pathophysiology and implications for management. Expert Review of Gastroenterology and Hepatology, 2013, 7, 127-139.	3.0	26
139	Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes. Advances in Therapy, 2013, 30, 81-101.	2.9	52
140	Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones. Diabetes Care, 2013, 36, 1396-1405.	8.6	255
141	Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans. Diabetes Care, 2013, 36, e202-e203.	8.6	51
142	Effects of Intraduodenal Glutamine on Incretin Hormone and Insulin Release, the Glycemic Response to an Intraduodenal Glucose Infusion, and Antropyloroduodenal Motility in Health and Type 2 Diabetes. Diabetes Care, 2013, 36, 2262-2265.	8.6	39
143	Physiology of the ageing gut. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 33-38.	2.5	46
144	Effects of a D-Xylose Preload With or Without Sitagliptin on Gastric Emptying, Glucagon-Like Peptide-1, and Postprandial Glycemia in Type 2 Diabetes. Diabetes Care, 2013, 36, 1913-1918.	8.6	45

#	Article	IF	CITATIONS
145	The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill. Diabetes Care, 2013, 36, 3333-3336.	8.6	20
146	Effects of variations in intragastric volume on blood pressure and splanchnic blood flow during intraduodenal glucose infusion in healthy older subjects. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R391-R399.	1.8	20
147	Effects of variations in duodenal glucose load on blood pressure, heart rate, superior mesenteric artery blood flow and plasma noradrenaline in healthy young and older subjects. Clinical Science, 2012, 122, 271-279.	4.3	22
148	A 25-Year Longitudinal Evaluation of Gastric Emptying in Diabetes. Diabetes Care, 2012, 35, 2594-2596.	8.6	52
149	Randomized double-blind crossover study to determine the effects of erythromycin on small intestinal nutrient absorption and transit in the critically ill. American Journal of Clinical Nutrition, 2012, 95, 1396-1402.	4.7	45
150	Comparative Effects of Variations in Duodenal Glucose Load on Glycemic, Insulinemic, and Incretin Responses in Healthy Young and Older Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 844-851.	3.6	61
151	Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. American Journal of Clinical Nutrition, 2012, 95, 78-83.	4.7	136
152	Physiology of the Antral Pump and Gastric Emptying. , 2012, , 959-976.		6
153	Diabetic Gastroparesis. , 2012, , 177-190.		0
154	Diabetic gastroparesisâ€"Backwards and forwards. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 46-57.	2.8	35
155	Gastric Emptying, Incretin Hormone Secretion, and Postprandial Glycemia in Cystic Fibrosis—Effects of Pancreatic Enzyme Supplementation. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E851-E855.	3.6	76
156	Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. Experimental Diabetes Research, 2011, 2011, 1-10.	3.8	75
157	Effects of small intestinal glucose load on blood pressure, splanchnic blood flow, glycemia, and GLP-1 release in healthy older subjects. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R1524-R1531.	1.8	35
158	Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*. Critical Care Medicine, 2010, 38, 1261-1269.	0.9	88
159	Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. American Journal of Physiology - Renal Physiology, 2010, 299, G1326-G1333.	3.4	11
160	Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 215-221.	3.6	196
161	Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. British Journal of Nutrition, 2010, 104, 803-806.	2.3	117
162	Effects of gastric distension on blood pressure and superior mesenteric artery blood flow responses to intraduodenal glucose in healthy older subjects. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R960-R967.	1.8	24

#	Article	IF	Citations
163	Effects of Physiological Hyperglycemia on Duodenal Motility and Flow Events, Glucose Absorption, and Incretin Secretion in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3893-3900.	3.6	21
164	Diabetic Gastroparesis and Its Impact on Glycemia. Endocrinology and Metabolism Clinics of North America, 2010, 39, 745-762.	3.2	35
165	Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans. Regulatory Peptides, 2010, 159, 156-159.	1.9	6
166	Dietary Effects on Incretin Hormone Secretion. Vitamins and Hormones, 2010, 84, 81-110.	1.7	45
167	Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. American Journal of Physiology - Renal Physiology, 2009, 296, G735-G739.	3.4	201
168	Effects of a Protein Preload on Gastric Emptying, Glycemia, and Gut Hormones After a Carbohydrate Meal in Diet-Controlled Type 2 Diabetes. Diabetes Care, 2009, 32, 1600-1602.	8.6	318
169	Insulin secretion in healthy subjects and patients with Type 2 diabetes – role of the gastrointestinal tract. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 413-424.	4.7	23
170	Diabetic Gastroparesis. Drugs, 2009, 69, 971-986.	10.9	76
171	Pathophysiology and management of gastroparesis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 167-181.	3.0	34
172	Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery. Regulatory Peptides, 2008, 146, 1-3.	1.9	11
173	Effects of mid-jejunal compared to duodenal glucose infusion on peptide hormone release and appetite in healthy men. Regulatory Peptides, 2008, 150, 38-42.	1.9	23
174	Effects of ginger on gastric emptying and motility in healthy humans. European Journal of Gastroenterology and Hepatology, 2008, 20, 436-440.	1.6	95
175	Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. American Journal of Physiology - Renal Physiology, 2007, 292, G1099-G1104.	3.4	39
176	Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E743-E753.	3.5	169
177	Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects. American Journal of Clinical Nutrition, 2007, 86, 1364-1368.	4.7	114
178	The diabetic gut – both aching and unfeeling?. Pain, 2007, 131, 239-240.	4.2	3
179	Gastric Emptying, Diabetes, and Aging. Clinics in Geriatric Medicine, 2007, 23, 785-808.	2.6	30
180	Pathophysiology and Management of Diabetic Gastropathy. Drugs, 2007, 67, 1671-1687.	10.9	29

#	Article	lF	CITATION
181	An update on autonomic neuropathy affecting the gastrointestinal tract. Current Diabetes Reports, 2006, 6, 417-423.	4.2	42
182	Effects of Fat on Gastric Emptying of and the Glycemic, Insulin, and Incretin Responses to a Carbohydrate Meal in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2062-2067.	3.6	286
183	The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E647-E655.	3.5	109
184	Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited?. Journal of Clinical Investigation, 2006, 116, 299-302.	8.2	54
185	Upper gastrointestinal function and glycemic control in diabetes mellitus. World Journal of Gastroenterology, 2006, 12, 5611.	3.3	34
186	Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E504-E507.	3.5	57
187	New management approaches for gastroparesis. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 454-462.	1.7	47
188	Upper gastrointestinal responses to intraduodenal nutrient in type 1 diabetes mellitus. European Journal of Gastroenterology and Hepatology, 2004, 16, 183-189.	1.6	7
189	Effect of hyperglycemia on triggering of transient lower esophageal sphincter relaxations. American Journal of Physiology - Renal Physiology, 2004, 286, G797-G803.	3.4	26
190	Gastroparesis: Prevalence, Clinical Significance and Treatment. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 805-813.	1.7	97
191	Proximal Gastric Compliance and Perception of Distension in Type 1 Diabetes Mellitus: Effects of Hyperglycemia. American Journal of Gastroenterology, 2000, 95, 1175-1183.	0.4	61